Friday, August 1, 2014

Roth ups Palatin price target

November 8, 2012 by · Leave a Comment 

Roth Capital Partners has raised its price target on “buy-rated” Palatin Technologies (AMEX:PTN) to $6 from $4.75 after the company said its Phase 2b study of bremelanotide in female sexual dysfunction (FSD) achieved its primary endpoint of showing statistically significant improvement in the number of sexually satisfying events, compared with placebo. The stock closed at 65 cents on Wednesday.

Results of the study are slated to determine the design (dosing and endpoints) of Phase 3 trials in FSD, which could begin in the second half of 2013.

“We expect that this catalyst could provide important visibility into Palatin’s FSD program and provide confidence to investors and to potential partners,” writes analyst Joseph Pantginis.

“We believe that the company is taking a differentiated approach, in contrast to high profile failures in the space, by testing its product candidate ‘as needed’ and potentially reducing bias in the placebo arm through monthly assessment of patient reported endpoints,” he added.

Beyond FSD, Palatin’s partner AstraZeneca remains committed to the collaborative program in obesity, with compounds in various stages of preclinical development as advanced as toxicology testing, ready to enter the clinic, Mr. Pantginis said.

Print Friendly

Comments are closed.

Email Newsletters with Constant Contact
Google+